Literature DB >> 11516064

Female genital warts: global trends and treatments.

S A Gall1.   

Abstract

The increasing incidence of human papillomavirus (HPV) infection and HPV-associated conditions such as genital warts in women is a global concern. Genital warts are a clinical manifestation of HPV types 6 and 11, and are estimated to affect 1% of sexually active adults aged between 15 and 49. HPV infection is also strongly associated with cervical cancer, and is prevalent in as many as 99% of cases. The psychological stress of having genital warts is often greater than the morbidity of the disease, and therefore successful treatment is crucial. Current treatments are patient-applied and provider-administered therapies. Imiquimod 5% cream, a patient-applied therapy, is an efficacious treatment with tolerable side-effects and a low recurrence rate, and has the potential to be an effective strategy for the management of genital warts.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11516064      PMCID: PMC1784648          DOI: 10.1155/S1064744901000278

Source DB:  PubMed          Journal:  Infect Dis Obstet Gynecol        ISSN: 1064-7449


  28 in total

Review 1.  Human papillomavirus infection and genital warts: update on epidemiology and treatment.

Authors:  K M Stone
Journal:  Clin Infect Dis       Date:  1995-04       Impact factor: 9.079

Review 2.  Human papillomavirus infection in women. Special aspects of infectious diseases in women.

Authors:  S Jablonska; S Majewski
Journal:  Clin Dermatol       Date:  1997 Jan-Feb       Impact factor: 3.541

Review 3.  Therapeutic approaches to genital warts.

Authors:  K R Beutner; A Ferenczy
Journal:  Am J Med       Date:  1997-05-05       Impact factor: 4.965

4.  The association of smoking and risk of condyloma acuminatum in women.

Authors:  J G Feldman; K Chirgwin; J A Dehovitz; H Minkoff
Journal:  Obstet Gynecol       Date:  1997-03       Impact factor: 7.661

5.  History of genital warts in 10,838 women 20 to 29 years of age from the general population. Risk factors and association with Papanicolaou smear history.

Authors:  C Munk; E I Svare; P Poll; J E Bock; S K Kjaer
Journal:  Sex Transm Dis       Date:  1997-11       Impact factor: 2.830

Review 6.  Epidemiology of anogenital warts and cancer.

Authors:  E L Franco
Journal:  Obstet Gynecol Clin North Am       Date:  1996-09       Impact factor: 2.844

7.  Immunological events in regressing genital warts.

Authors:  N Coleman; H D Birley; A M Renton; N F Hanna; B K Ryait; M Byrne; D Taylor-Robinson; M A Stanley
Journal:  Am J Clin Pathol       Date:  1994-12       Impact factor: 2.493

8.  Cancer associated human papillomaviruses: perinatal transmission and persistence.

Authors:  F Pakarian; J Kaye; J Cason; B Kell; R Jewers; N W Derias; K S Raju; J M Best
Journal:  Br J Obstet Gynaecol       Date:  1994-06

9.  Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions.

Authors:  K U Petry; D Scheffel; U Bode; T Gabrysiak; H Köchel; E Kupsch; M Glaubitz; S Niesert; H Kühnle; I Schedel
Journal:  Int J Cancer       Date:  1994-06-15       Impact factor: 7.396

10.  Spectrum of genital human papillomavirus infection in a female adolescent population.

Authors:  J H Jamison; D W Kaplan; R Hamman; R Eagar; R Beach; J M Douglas
Journal:  Sex Transm Dis       Date:  1995 Jul-Aug       Impact factor: 2.830

View more
  7 in total

Review 1.  New approach to managing genital warts.

Authors:  Catharine C Lopaschuk
Journal:  Can Fam Physician       Date:  2013-07       Impact factor: 3.275

2.  Topical application of temperature-sensitive caerin 1.1 and 1.9 gel inhibits TC-1 tumor growth in mice.

Authors:  Bowei Ma; Jianwei Yuan; Shu Chen; Kunsong Huang; Qianbo Wang; Jianchun Ma; Ruoting Lin; Lu Zhang; Yingying Zhou; Tianfang Wang; Shelley F Walton; Xuan Pan; Guoqiang Chen; Yuejian Wang; Guoying Ni; Xiaosong Liu
Journal:  Am J Transl Res       Date:  2020-01-15       Impact factor: 4.060

Review 3.  Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions.

Authors:  Anna R Giuliano; Guillermo Tortolero-Luna; Elena Ferrer; Ann N Burchell; Silvia de Sanjose; Susanne Kruger Kjaer; Nubia Muñoz; Mark Schiffman; F Xavier Bosch
Journal:  Vaccine       Date:  2008-08-19       Impact factor: 3.641

Review 4.  HPV infection in urology practice.

Authors:  Mehmet Sarier; Ali Murat Ceyhan; Nevgun Sepin; Esin Ozel; Mehmet Murat Inal; Erdal Kukul; Ahmet Soylu
Journal:  Int Urol Nephrol       Date:  2019-10-03       Impact factor: 2.370

5.  Individual- and regional-level determinants of human papillomavirus (HPV) vaccine refusal: the Ontario Grade 8 HPV vaccine cohort study.

Authors:  Olivia Remes; Leah M Smith; Beatriz E Alvarado-Llano; Lindsey Colley; Linda E Lévesque
Journal:  BMC Public Health       Date:  2014-10-08       Impact factor: 3.295

6.  Risk factors for aggressive recurrent respiratory papillomatosis in adults and juveniles.

Authors:  Turid Omland; Harriet Akre; Kathrine A Lie; Peter Jebsen; Leiv Sandvik; Kjell Brøndbo
Journal:  PLoS One       Date:  2014-11-24       Impact factor: 3.240

7.  Cross-sectional study estimating the psychosocial impact of genital warts and other anogenital diseases in South Korea.

Authors:  Taek Sang Lee; Smita Kothari-Talwar; Puneet K Singhal; Karen Yee; Amit Kulkarni; Nuria Lara; Montserrat Roset; Anna R Giuliano; Suzanne M Garland; Woong Ju
Journal:  BMJ Open       Date:  2019-03-20       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.